Literature DB >> 26797234

Changes in Quality of Life Associated with Complications of Diabetes: Results from the ADVANCE Study.

Alison Hayes1, Hisatomi Arima2, Mark Woodward3, John Chalmers4, Neil Poulter5, Pavel Hamet6, Philip Clarke7.   

Abstract

OBJECTIVE: To measure the impact of complications on summary measures of health-related quality of life among people with type 2 diabetes.
METHODS: Patients participating in the Action in Diabetes and Vascular Disease:Preterax and Diamicron MR Controlled Evaluation (ADVANCE) trial were administered a health-related quality-of-life questionnaire, the three-level EuroQol five-dimensional questionnaire (EQ-5D-3L), on four occasions over a 5-year period. We used two-way fixed-effects longitudinal regression models to investigate the impact of incident diabetes complications (stroke, heart failure, myocardial infarction, ischemic heart disease, renal failure, blindness, and amputation) on EQ-5D-3L utility score (where 1 = perfect health), while controlling for characteristics of individuals that do not vary over time.
RESULTS: The effect of having any one of the seven complications was to reduce the EQ-5D-3L utility score by 0.054 (95% confidence interval 0.044-0.064), and this was not significantly affected by baseline age, sex, economic region, or the value set used to derive utilities. The complication with the largest disutility was amputation (0.122), followed by stroke (0.099), blindness (0.083), renal failure (0.049), heart failure (0.045), and myocardial infarction (0.026). Ischemic heart disease did not significantly reduce the utility score. Quality of life also declined with elapsed time-by an average of 0.006 per year, in addition to the effect of complications.
CONCLUSIONS: Common complications significantly reduce health-related quality of life. Utility scores derived from the EQ-5D-3L provide a potential measure that can be used to summarize patient-reported outcomes and inform health economic models. Prevention of complications is critical to reduce the progressive burden of declining quality of life for people with diabetes.
Copyright © 2016 International Society for Pharmacoeconomics and Outcomes Research (ISPOR). Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  complications; longitudinal analysis; quality of life; type 2 diabetes

Mesh:

Year:  2015        PMID: 26797234     DOI: 10.1016/j.jval.2015.10.010

Source DB:  PubMed          Journal:  Value Health        ISSN: 1098-3015            Impact factor:   5.725


  31 in total

1.  Estimating Quality of Life Decrements Due to Diabetes Complications in the United States: The Health Utility Index (HUI) Diabetes Complication Equation.

Authors:  Hui Shao; Shuang Yang; Vivian Fonseca; Charles Stoecker; Lizheng Shi
Journal:  Pharmacoeconomics       Date:  2019-07       Impact factor: 4.981

2.  Illness Perceptions Mediate the Impact of Depressive Symptoms on Quality of Life Among Latinos with Type 2 Diabetes.

Authors:  Alexandra A García; Ya-Ching Huang; Julie A Zuñiga
Journal:  J Immigr Minor Health       Date:  2022-02-23

3.  Estimated Life-Years Gained Free of New or Recurrent Major Cardiovascular Events With the Addition of Semaglutide to Standard of Care in People With Type 2 Diabetes and High Cardiovascular Risk.

Authors:  Jan Westerink; Kasper Sommer Matthiessen; Solomon Nuhoho; Udi Fainberg; Michael Lyng Wolden; Helena Bleken Østergaard; Frank Visseren; Naveed Sattar
Journal:  Diabetes Care       Date:  2022-05-01       Impact factor: 17.152

4.  HRQOL in Diverse Ethnic Groups with Diabetes: Findings from the 2014 BRFSS.

Authors:  Kelley Newlin Lew; Julie Wagner; Omar Braizat
Journal:  J Racial Ethn Health Disparities       Date:  2018-03-14

5.  Cost-effectiveness of Community-Based Depression Interventions for Rural and Urban Adults With Type 2 Diabetes: Projections From Program ACTIVE (Adults Coming Together to Increase Vital Exercise) II.

Authors:  Shihchen Kuo; Wen Ye; Mary de Groot; Chandan Saha; Jay H Shubrook; W Guyton Hornsby; Yegan Pillay; Kieren J Mather; William H Herman
Journal:  Diabetes Care       Date:  2021-02-19       Impact factor: 19.112

6.  Cost-Effectiveness of Saxagliptin Compared With Glibenclamide as a Second-Line Therapy Added to Metformin for Type 2 Diabetes Mellitus in Ethiopia.

Authors:  Mengistu Bekele; Ole Frithjof Norheim; Alemayehu Hailu
Journal:  MDM Policy Pract       Date:  2021-04-27

7.  Patient Health Utility Equations for a Type 2 Diabetes Model.

Authors:  Simon J Neuwahl; Ping Zhang; Haiying Chen; Hui Shao; Michael Laxy; Andrea M Anderson; Timothy E Craven; Thomas J Hoerger
Journal:  Diabetes Care       Date:  2020-12-04       Impact factor: 17.152

Review 8.  Sodium-glucose Cotransporter-2 Inhibitors: Moving Beyond the Glycemic Treatment Goal.

Authors:  Vishal Gupta; William Canovatchel; B N Lokesh; Ravi Santani; Nishant Garodia
Journal:  Indian J Endocrinol Metab       Date:  2017 Nov-Dec

9.  Association between Sleep Quality and Painless Diabetic Peripheral Neuropathy Assessed by Current Perception Threshold in Type 2 Diabetes Mellitus.

Authors:  Dughyun Choi; Bo-Yeon Kim; Chan-Hee Jung; Chul-Hee Kim; Ji-Oh Mok
Journal:  Diabetes Metab J       Date:  2020-08-06       Impact factor: 5.376

10.  How psychosocial outcomes impact on the self-reported health status in type 2 diabetes patients: Findings from the Diabetes Attitudes, Wishes and Needs (DAWN) study in eastern China.

Authors:  Haijian Guo; Xuanxuan Wang; Tao Mao; Xiaoning Li; Ming Wu; Jiaying Chen
Journal:  PLoS One       Date:  2018-01-25       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.